RE:RE:The breadcrumbs I see in the IRWhat's the likelihood that a Dialco sale is already being finalized and they are now tying up loose ends?
Consider:
1. The ongoing DIMI useability trial delays on what should be the easiest to execute trial ever in the history of the FDA. In the May 13, 2022 PR it is stated that "The Dialco team...expects first patient enrollment in Q3 2022". This didn't happen or it hasn't been disclosed. Was the goal all along to tee up the outstanding trials to certain milestones as a prerequisite/condition of the sale?
2. Current round of financing excludes Dialco. A trial that is supposed to be enrolling patients right now needs funding right now. I'm getting the sense that there was no intention at all of performing the DIMI trial by this team.
3. Weirdness with Dialco/Infomed. Now they are working on: "Dialco has extended its DIMI license agreement with Infomed SA until November 30, 2022 as the parties evaluate strategic options for advancing DIMI". I thought that the Dialco/Infomed agreement was solid for the next decade. For what purpose are they tinkering with their agreement for the next two months?
4. The hiring of Sam Amory. He can pass along to the new owners while he finishes up his residency program at Dialco.
I hate trying to read between the lines!